Who we are
RMI LLC, a RUSNANO company, is Russia’s and Eastern Europe’s largest venture capital company specializing in investments in Life Sciences innovations
RMI LLC was created in March 2012 and invested by RUSNANO - the Russian development institution established for the investment in the field of Nanotechnology.
The key strategic objective of RMI LLC is to create a Russian-domiciled locus of world-class expertise in venture capital fundraising, deal origination and execution in Life Sciences, with a clear focus on innovative pharmaceutical projects backed by sustainable, cutting edge technologies.
RMI LLC is now evaluating a wide range of life sciences and pharmaceuticals investment opportunities with a view to investing in approximately 20 promising technologies and localizing these technologies in Russia.
Ultimately the goal of these investments and associated localization strategies is to significantly reduce the introduction lead time of new and innovative medicines and medical devices in Russia targeted at delivering significant therapeutic benefits and efficiencies in disease areas that are classified as socially significant complex, poorly treated and widely prevalent diseases in Russia in cases where no domestically sourced, effective treatment methods are available today.
All Portfolio
MEDIA CENTER
-
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.